As of July 13, 2022, approximately 53.7 million people in the United Kingdom had received the first dose of the COVID-19 vaccination. The UK was the first country in the world to approve the use of the Pfizer/BioNTech vaccine, and began inoculations on December 8, 2020. Nearly all the vaccines currently being used in the UK require two doses for full efficacy to occur, and according to the latest data around 50.3 million people had received their second dose of the immunization. Furthermore, 40.1 million booster vaccinations had been administered.

The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

The number of COVID-19 vaccination doses administered in the United Kingdom rose to 151248820 as of Oct 27 2023. This dataset includes a chart with historical data for the United Kingdom Coronavirus Vaccination Total.

As of January 18, 2023, Germany had administered over 190 million COVID-19 vaccine doses, while France had administered approximately 153.9 million doses. The United Kingdom was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of January 18, 2023, approximately 184 million COVID-19 vaccine doses had been administered in Russia.

The seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Request The NHSBSA makes payments for Covid-19 vaccinations to Primary Care Network (PCN) providers in England. May I request the following data, separated per administration month, starting from 1st June 2023 to 31st March 2024, in excel format: Column 1 Year/month Column 2 ODS Code for PCN Column 3 ICS Code for the PCN Column 4 ICS Name for the PCN Column 5 Number of vaccines administered by the PCN Column 6 Total Payment made for administration of these Covid-19 vaccinations Column 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN. Date Range: 01/06/2023 - 31/03/2024 Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information and notes explaining it is attached. Please read the below notes to ensure correct understanding of the data. Columns 2 and 3, ICS code and name I am writing to advise you that following a search of our paper and electronic records, I have established that the information you requested is not currently held by the NHS Business Services Authority. We do not hold the ICS for PCNs in our database. The ODS portal can be used to identify links to ICS or 'Integrated Care Board (ICB). This can be found at: https://odsportal.digital.nhs.uk/ Columns 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN Please note that NHSBSA do not hold information on miscellaneous payments, but column 7 shows information on 'adjustments' which could be either a payment or a deduction, following post-payment verification. The NHSBSA calculates payments for covid vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS, to be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines that have been 'claimed' and the number that have been 'paid'. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month This is the month in which the vaccine was administered to the patient. Payment Month This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month) As the claim is outside the submission window it is not paid in March, it will instead be paid during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. We do not hold PCN data that we can confidently join to the Lead PCN Practice ODS Code and so data is at Lead PCN Practice level. Data included in this request is limited to vaccinations carried out by PCNs only. Data included in this request is also limited to vaccinations administered between July 2023 and March 2024. The latest data used is a snapshot of the MYS system data that was taken on 8th April 2024. This is the snapshot of data taken after the March 2024 submission period that was used to calculate payments. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. These adjustments are made at account level and may relate to several months of activity. Payment data includes payments made and those scheduled for payment in the future. Payments comprise an Item of Service fee and potentially a Supplementary fee. Payments do not relate to the value of the drugs dispensed. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee. It is possible for new records from old administration months to be entered in the future, thus the totals here for each administration month could change when more data is processed.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of April 13, 2021, the United Kingdom government had ordered 457 million doses of various COVID-19 vaccines. The UK government has ordered 100 million doses each of the AstraZeneca and Valneva vaccines. On December 2, 2020, the UK became the first country in the world to approve the Pfizer/BioNTech vaccine, and the first inoculations took place six days later on December 8. The Pfizer/BioNTech immunization requires two injections several weeks apart for full immunity to occur, which means the initial order of 40 million doses is enough for 20 million individuals to be vaccinated. The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

The NHSBSA makes payments for Covid-19 vaccinations to Primary Care Network (PCN) providers in England. May I request the following data, separated per administration month, starting from 1st April 2024 to 31st August 2024, in excel format: Column 1 Year/month Column 2 ODS Code for PCN Column 3 ICS Code for the PCN Column 4 ICS Name for the PCN Column 5 Number of vaccines administered by the PCN Column 6 Total Payment made for administration of these Covid-19 vaccinations Column 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN. If the August data is not available at the time of processing this request then please can you send me the data for April-July Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information and notes explaining it is attached. Please read the below notes to ensure correct understanding of the data. Columns 2 and 3, Integrated Care Service (ICS) code and name I am writing to advise you that following a search of our paper and electronic records, I have established that the information you requested is not currently held by the NHS Business Services Authority. We do not hold the ICS for PCNs in our database. The ODS portal can be used to identify links to ICS or 'Integrated Care Board (ICB). This can be found at: https://odsportal.digital.nhs.uk/ Columns 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN Please note that NHSBSA do not hold information on miscellaneous payments, but column 7 shows information on 'adjustments' which could be either a payment or a deduction, following post-payment verification. The NHSBSA calculates payments for covid vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines that have been 'claimed' and the number that have been 'paid'. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month This is the month in which the vaccine was administered to the patient. Payment Month This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month) As the claim is outside the submission window it is not paid in March, it will instead be paid during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. We do not hold PCN data that we can confidently join to the Lead PCN Practice ODS Code and so data is at Lead PCN Practice level. Data included in this request is limited to vaccinations carried out by PCNs only. Data included in this request is also limited to vaccinations administered between April 2024 and August 2024. The latest data used is a snapshot of the MYS system data that was taken on 6th September 2024. This is the snapshot of data taken after the August 2024 submission period that was used to calculate payments. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. These adjustments are made at account level and may relate to several months of activity. Payment data includes payments made and those scheduled for payment in the future. Payments comprise an Item of Service fee and potentially a Supplementary fee. Payments do not relate to the value of the drugs dispensed. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee. It is possible for new records from old administration months to be entered in the future, thus the totals here for each administration month could change when more data is processed.

Flu vaccine uptake (%) in children aged 2 to 3 years old, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in those aged 2 to 3 years old. Prior to this, the national vaccine uptake ambition was 75% in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsThis collection has received approval from the Data Coordination Board (DCB).Data is final and represents a percentage of all GP practices in England responding to the final survey. Where a total for England is quoted (e.g., a sum of the number of patients registered and number vaccinated), this is taken from the GP practice sample and is therefore not an extrapolated figure.For definitions of clinical at-risk groups for those aged 6 months to under 65 years, see the annual flu letter published at Annual Flu Programme.The age under 65 clinical at-risk group data includes pregnant women with other risk factors but excludes otherwise 'healthy' pregnant women and carers.All figures are derived from data as extracted from records on GP systems or as submitted by GP practices, Area Teams, and CCGs.Data source: ImmForm website: registered patient GP practice data, Influenza Immunisation Vaccine Uptake Monitoring Programme, OHID.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2023-24. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

The name and postcode of the GP practice or PCN. The submission date. The number of vaccines administered. The payment made or to be made. Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information is attached. Please read the notes to ensure correct understanding of the data. The NHSBSA calculates payments for Covid-19 vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid19 vaccination data is keyed in via Point of Care (POC) Systems and then transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion, claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period, they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines ‘claimed' and the number that have been 'paid'. We do not hold Primary Care Network (PCN) Grouping data that we can confidently join to the GP Practice Organisation Data Service (ODS) Code. Data is provided for the GP Practice ODS Code that represented its whole PCN Grouping for the purpose of claiming fees for Covid-19 vaccines. The names, addresses and postcodes of GP practices is publicly available via the NHS Digital ODS data here https://digital.nhs.uk/services/organisation-data-service/export-data-files/csv-downloads/gp-and-gp-practice-related-data Each provided ODS code can be linked to GP practice address and post code data in the epraccur dataset or using other ODS tools such as ODS portal search or ODS data point. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. We have included values for the total payment calculated, with an additional column for any ancillary payment calculated after the original payment. Data included in this request is limited to vaccinations carried out by PCNs only. As requested, we have chosen to report by Submission Date. Data included in this request is also limited to vaccinations administered between December 2020 and August 2024. The latest data used is a snapshot of the MYS system data that was taken on Friday 6 September 2024. This is the snapshot of data taken after the August 2024 submission period that was used to calculate payments. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. Any adjustments are made at account level and may relate to several months of activity. This data does not include data for claim submissions made in February 2021, as these were deleted and resubmitted later to apply the revised fee rates. In this month, there was a clawback of some payments and most of these clawbacks are excluded from this report and with the data reported against the resubmission. But during this period, there were some manual adjustments that may not all be reflected in the itemised records. Payment data includes payments made and any scheduled for payment in the future. Payments comprise of an Item of Service fee and a supplementary fee where applicable. Payments do not relate to the value of the drugs dispensed. For doses administered between September 2021 and January 2022, there was a range of late notice fee rate changes. Over this time, the pre-established rates were claimed and paid as normal. Top up payments were made later in February, March and May 2022 to bring the total paid to that implied by the late notice fee rate changes. These top ups were calculated separately, but they did not require a new submission - so these have been reported against the original submission date for the dose that would have led to the standard payment. These top up payments are shown as 'Ancillary Payment Amount GBP'. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. This report may include claims for tokens that have exceeded the applicable grace period (currently 3 months) at the time they were processed; such doses will not be included in the payment. This report does not include data for doses claimed after the 15-day period between date supplied and date recorded in the point of care system. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee.

Covid vaccinations administered by local area since 8th December 2020. It includes the calculated percentage of the 12+ population who have received all required vaccinations and/or boosters.Population estimates are based on National Immunisation Management Service counts.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

All children for whom the local authority is responsible who received one dose of MMR on or after their first birthday and at any time up to their second birthday as a percentage of all children whose second birthday falls within the time period.RationaleMMR is the combined vaccine that protects against measles, mumps and rubella. Measles, mumps and rubella are highly infectious, common conditions that can have serious complications, including meningitis, swelling of the brain (encephalitis) and deafness. They can also lead to complications in pregnancy that affect the unborn baby and can lead to miscarriage.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The first MMR vaccine is given to children as part of the routine vaccination schedule, usually within a month of their first birthday. They'll then have a booster dose before starting school, which is usually between three and five years of age. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels.May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorTotal number of children whose second birthday falls within the time period who received one dose of MMR on or after their first birthday and at any time before their second birthday.Data for 2013 to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.Definition of denominatorTotal number of children whose second birthday falls within the time period.Data from 2013to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental data and should be treated with caution. It is not an official statistic.

As of July 17, 2022, it was estimated that around every person aged 75 to 79 years of age in England had received at least two doses of a COVID-19 vaccine. Although the source does mention that this is likely to be an overestimation due to population figures taken from 2020. The data shows that at least a quarter of men under 30 years of age have not yet had two vaccine doses, with women more likely to be vaccinated among younger age groups.